Patents by Inventor Andreas Evers

Andreas Evers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240287177
    Abstract: VHH-based NKp30 binders are provided having favorable characteristics. Moreover, pharmaceutical compositions including such a compound are produced and methods of medical treatment with such compounds and pharmaceutical compositions are developed. In a compound including a VHH antibody domain or fragment thereof, the VHH antibody domain or fragment thereof can have complementary determining regions CDR1, CDR2, and CDR3 of one of VHH1 to VHH16, or a humanized modification thereof, or a modification involving replacement, addition, and/or deletion of up to three amino acids in each complementary determining region.
    Type: Application
    Filed: June 22, 2022
    Publication date: August 29, 2024
    Applicant: Merck Patent GmbH
    Inventors: Stefan ZIELONKA, Lars Toleikis, Simon Krah, Lukas Pekar, Andreas Evers
  • Publication number: 20230127047
    Abstract: The present invention relates to GIP(1-30) analogues which selectively bind and activate the GIP receptor and comprise a chelating moiety capable of binding a metal ion and their use, for example in PET imaging or for radiotherapy.
    Type: Application
    Filed: March 30, 2021
    Publication date: April 27, 2023
    Inventors: Andreas Evers, Michael Wagner, Torsten Haack, Martin Bossart, Katrin Lorenz
  • Patent number: 11141489
    Abstract: The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-L-Y—R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising the conjugate or the pharmaceutically acceptable salt thereof as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: October 12, 2021
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Michael Wagner, Thomas Olpp, Nino Meyer, Martin Bossart, Andreas Evers, Peyman Sakhaii, Pradeep K. Dhal, Paul Konowicz, James E. Stefano, Nils Poth
  • Patent number: 11046743
    Abstract: The present invention relates to exendin-4 peptide analogues which selectively bind and activate the glucagon receptor and comprise a chelating moiety capable of binding a metal ion and their use, for example in PET imaging.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: June 29, 2021
    Assignee: ANTAROS MEDICAL AB
    Inventors: Torsten Haack, Oliver Plettenburg, Andreas Evers, Michael Wagner, Martin Bossart, Romain Bertrand
  • Patent number: 10806797
    Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon agonist linker conjugate Z-L1-L2-L-Y—R20, wherein Y represents an GLP-1/Glucagon agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon agonist.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: October 20, 2020
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Michael Wagner, Thomas Olpp, Nino Meyer, Pradeep Dhal, Paul Konowicz, Robert Miller, James Stefano, Magnus Besev, Martin Bossart, Katrin Lorenz, Torsten Haack, Andreas Evers
  • Patent number: 10792367
    Abstract: The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y—R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising the conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: October 6, 2020
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Michael Wagner, Thomas Olpp, Nino Meyer, Martin Bossart, Andreas Evers, Peyman Sakhaii, Pradeep K. Dhal, Paul Konowicz, James E. Stefano, Nils Poth
  • Patent number: 10758592
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: September 1, 2020
    Assignee: SANOFI
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart
  • Patent number: 10583174
    Abstract: The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 10, 2020
    Assignee: SANOFI
    Inventors: Britta Göbel, Mark Sommerfeld, Oliver Boscheinen, Thomas Langer, Christine Rudolph, Andreas Evers
  • Patent number: 10538567
    Abstract: The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: January 21, 2020
    Assignee: SANOFI
    Inventors: Martin Bossart, Andreas Evers, Torsten Haack, Dieter Kadereit, Katrin Lorenz, Michael Wagner, Stefania Pfeiffer-Marek, Martin Lorenz
  • Patent number: 10519211
    Abstract: The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: December 31, 2019
    Assignee: SANOFI
    Inventors: Martin Bossart, Andreas Evers, Torsten Haack, Katrin Lorenz, Dieter Kadereit, Michael Wagner, Stefania Pfeiffer-Marek, Martin Lorenz
  • Patent number: 10253079
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: April 9, 2019
    Assignee: SANOFI
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Lorenz, Katrin Lorenz
  • Publication number: 20180185450
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Application
    Filed: December 11, 2017
    Publication date: July 5, 2018
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart
  • Patent number: 9982029
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: May 29, 2018
    Assignee: SANOFI
    Inventors: Martin Bossart, Andreas Evers, Torsten Haack, Katrin Lorenz, Dieter Kadereit, Michael Wagner, Bernd Henkel
  • Patent number: 9932381
    Abstract: The present invention relates to glucagon receptor agonists and their medical use, for example in the treatment of severe hypoglycemia.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: April 3, 2018
    Assignee: Sanofi
    Inventors: Torsten Haack, Siegfried Stengelin, Andreas Evers, Michael Wagner, Bernd Henkel
  • Patent number: 9834527
    Abstract: The present invention relates to macrocydic urea derivatives of the formula I (I) in which R1, R2, R3, V and Y are as defined below. The compounds of the formula I are inhibitors of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor). The invention further relates to the process for the preparation of the compounds of formula I and to the use thereof as medicaments.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: December 5, 2017
    Assignee: SANOFI
    Inventors: Andreas Evers, Christopher Kallus, Michael Wagner, Hermut Wehlan
  • Patent number: 9789165
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: October 17, 2017
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Katrin Lorenz, Andreas Evers, Torsten Haack, Michael Wagner, Bernd Henkel, Martin Lorenz, Siegfried Stengelin
  • Patent number: 9775904
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: October 3, 2017
    Assignee: SANOFI
    Inventors: Martin Bossart, Ralf Elvert, Andreas Evers, Torsten Haack, Siegfried Stengelin, Michael Wagner
  • Patent number: 9771406
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists or optionally trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: September 26, 2017
    Assignee: SANOFI
    Inventors: Martin Bossart, Ralf Elvert, Andreas Evers, Torsten Haack, Siegfried Stengelin, Michael Wagner, Katrin Lorenz
  • Patent number: 9758561
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: September 12, 2017
    Assignee: SANOFI
    Inventors: Martin Bossart, Ralf Elvert, Andreas Evers, Torsten Haack, Siegfried Stengelin, Michael Wagner, Dieter Kadereit
  • Patent number: 9751926
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 5, 2017
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Katrin Lorenz, Andreas Evers, Torsten Haack, Michael Wagner, Bernd Henkel, Martin Lorenz, Siegfried Stengelin